PT - JOURNAL ARTICLE AU - Meng, Weimin AU - Inampudi, Rohit AU - Zhang, Xiang AU - Xu, Jie AU - Huang, Yu AU - Xie, Mingyi AU - Bian, Jiang AU - Yin, Rui TI - An Interpretable Population Graph Network to Identify Rapid Progression of Alzheimer’s Disease Using UK Biobank AID - 10.1101/2024.03.27.24304966 DP - 2024 Jan 01 TA - medRxiv PG - 2024.03.27.24304966 4099 - http://medrxiv.org/content/early/2024/03/28/2024.03.27.24304966.short 4100 - http://medrxiv.org/content/early/2024/03/28/2024.03.27.24304966.full AB - Alzheimer’s disease (AD) manifests with varying progression rates across individuals, necessitating the understanding of their intricate patterns of cognition decline that could contribute to effective strategies for risk monitoring. In this study, we propose an innovative interpretable population graph network framework for identifying rapid progressors of AD by utilizing patient information from electronic health-related records in the UK Biobank. To achieve this, we first created a patient similarity graph, in which each AD patient is represented as a node; and an edge is established by patient clinical characteristics distance. We used graph neural networks (GNNs) to predict rapid progressors of AD and created a GNN Explainer with SHAP analysis for interpretability. The proposed model demonstrates superior predictive performance over the existing benchmark approaches. We also revealed several clinical features significantly associated with the prediction, which can be used to aid in effective interventions for the progression of AD patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially supported by grants from Centers for Disease Control and Prevention (1U18DP006512), National Institute of Environmental Health Sciences (R21ES032762) and the NIH National Center for Advancing Translational Sciences (UL1TR001427).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research has been conducted using the UK Biobank Resource under Application Number 95030. Data in this study are available in a public, open access repository. The UK Biobank data are available on application to the UK Biobank (www.ukbiobank.ac.uk/) with access fees.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available with access fee upon reasonable request to https://www.ukbiobank.ac.uk/. The data can be accessed via the UKB research analysis platform (RAP): https://ukbiobank.dnanexus.com/landing. https://www.ukbiobank.ac.uk/ https://github.com/UF-HOBI-Yin-Lab/ADGraph/